Iambic Announces Pricing of Initial Public Offering
SAN DIEGO--(BUSINESS WIRE)--Oct 14, 2026-- Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pricing of its initial public …